Aptose Biosciences Inc. logo
Aptose Announces Reverse Share Split
February 18, 2025 16:30 ET | Aptose Biosciences, Inc.
Aptose Announces Reverse Share Split
Aptose Biosciences Inc. logo
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility
February 13, 2025 16:30 ET | Aptose Biosciences, Inc.
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility
Aptose Biosciences Inc. logo
Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial
February 12, 2025 07:00 ET | Aptose Biosciences, Inc.
Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial
Aptose Biosciences Inc. logo
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
January 09, 2025 16:00 ET | Aptose Biosciences, Inc.
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
Aptose Biosciences Inc. logo
Aptose Announces Positive Decision by Nasdaq Hearings Panel
December 19, 2024 16:05 ET | Aptose Biosciences, Inc.
Aptose Announces Positive Decision by Nasdaq Hearings Panel
Aptose Biosciences Inc. logo
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
December 12, 2024 10:15 ET | Aptose Biosciences, Inc.
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells
Aptose Biosciences Inc. logo
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
December 09, 2024 12:00 ET | Aptose Biosciences, Inc.
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
Aptose Biosciences Inc. logo
Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
December 03, 2024 07:30 ET | Aptose Biosciences, Inc.
Aptose's AML drug tuspetinib selected for NCI's prestigious clinical research program for ability to target broad spectrum of AML and MDS populations
Aptose Biosciences Inc. logo
Aptose Reports Results for the Third Quarter 2024
November 08, 2024 16:01 ET | Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Biosciences Inc. logo
Aptose Announces Results from Special Meeting of Shareholders
September 05, 2024 16:15 ET | Aptose Biosciences, Inc.
Aptose Announces Results from Special Meeting of Shareholders